The level of miR-216b in MeWo melanoma cells carrying the wild-type BRAF gene was not significantly altered by vemurafenib, suggesting an association between miR-216b downregulation upon vemurafenib treatment and BRAF mutations [38]. This evidence concerns the gene BRAF and melanoma.